Fact Sheet — Second MFN Drug Pricing Deal (AstraZeneca)

Fact Sheet — Second MFN Drug Pricing Deal (AstraZeneca)Announces a second Most-Favored-Nation (MFN) pricing agreement, this time with AstraZeneca, aligning U.S. prices to the lowest paid in peer nations.Medicaid impact: All state Medicaid programs gain access to MFN prices on AstraZeneca drugs; projected savings in the hundreds of millions.Patient discounts: Direct-to-patient sales include deep list-price discounts:Scope: Ensures MFN pricing on all new AstraZeneca innovative medicines; requires repatriation of increased foreign revenue to benefit U.S. patients.Investment: AstraZeneca to invest $50B in U.S. manufacturing/R&D by 2030; new Charlottesville, VA facility creating 3,600 jobs.Context: Follows a Sept 30, 2025 MFN deal with Pfizer; part of broader push to curb higher U.S. brand-name drug prices vs. other OECD countries.